Home / News
Mission updates
Track strategic developments and technical progress from across the Axplora network. These include corporate announcements, expert insights, expansion news and industry updates.
News
August 05, 2026
Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network
Science Based Targets initiative (SBTi) validation provides independent confirmation of Axplora’s emissions-reduction targets. Targets reinforce Axplora’s commitment to helping customers build responsible, transparent and resilient pharmaceutical supply chains. Axplora’s ActNow 2030 initiative commits to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. July 2026 – Axplora, a […]
News
July 09, 2026
Axplora’s European CDMO network raises the bar with enhanced EcoVadis ratings across four manufacturing sites
Axplora’s Leverkusen site was awarded Platinum, with Le Mans receiving Gold, and Pompey and Chasse-sur-Rhône Silver in their first individual EcoVadis assessments. Recognition reinforces Axplora’s commitment to helping customers navigate increasingly complex supply chains with confidence through responsible, transparent and reliable manufacturing. 9 July, 2026 – Axplora, a global CDMO Partner for complex […]
News
June 10, 2026
Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen focus on Steroids and HPAPI leadership June 10th, 2026 – Axplora, a global leader in the manufacturing of small molecule APIs and ADCs for the pharmaceutical industry, today announced the strategic consolidation of ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India site, part of the PharmaZell business unit. Production will transition fully from the […]
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
News
March 17, 2026
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site 18 February, 2026 – Axplora, a global CDMO Partner for complex small molecules and antibody-drug conjugates (ADCs), today announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France Site strengthening its ability to deliver […]
Press Release
October 08, 2025
Axplora initiates global investments exceeding €100m in 2025
Raubling, 7 October, 2025 – Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its […]
News
August 05, 2025
Axplora Announces €6.5 Million Investment at Vizag Site and FDA Inspection Success Across Indian Operations
5 August 2025 Axplora, a global leader in API small molecule manufacturing, today announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the successful completion of routine USFDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of […]
Press Release
June 30, 2025
Axplora announces further €35M expansion at Farmabios to double footprint and fuel long-term growth
Axplora is proud to unveil a transformative €35 million expansion at its Farmabios site in Gropello Cairoli, Italy, reinforcing the company’s longstanding commitment to serving the evolving needs of its customers through strategic investment and innovation. This latest investment builds on the €45 million already committed over the past five years, bringing Axplora’s total recent […]
Article
June 11, 2025
Axplora Strategy Teardown: A Podcast
In a recent episode of the PharmaSource podcast, Arul Ramadurai, Chief Commercial Officer at Axplora, discusses the company’s strategic focus on high-growth therapeutic areas and its customer-driven investment philosophy. Strategic Focus on High-Growth Therapeutic Areas Axplora has positioned itself in two of the fastest-growing therapeutic areas: GLP-1 peptides and antibody-drug conjugates (ADCs). The company recently […]
Press Release
June 04, 2025
Axplora’s Chasse-sur-Rhône site successfully passes its ninth consecutive regulatory inspection
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is proud to announce that its Chasse-sur-Rhône CDMO site in France has successfully passed its latest on-site inspection by the French National Agency for Medicines and Health Products Safety (ANSM). Conducted in February 2025, the inspection confirmed the site’s full compliance with […]
Partner with us today
Clear your path to launch. Contact our technical experts to manage project complexities and secure your route to market.